The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Immunology and Immunotherapy of Head and Neck Cancer
Open accessAbstract
The immune system plays a key role in the development, establishment, and progression of head and neck squamous cell carcinoma (HNSCC). A greater understanding of the dysregulation and evasion of the immune system in the evolution and progression of HNSCC provides the basis for improved therapies and outcomes for patients. HNSCC cells evade the host immune system through manipulation of their own immunogenicity, production of immunosuppressive mediators, and promotion of immunomodulatory cell types. Through the tumor's influence on the microenvironment, the immune system can be exploited to promote metastasis, angiogenesis, and growth. This article provides a brief overview of key components of the immune infiltrating cells in the tumor microenvironment, reviewing immunological principles related to head and neck cancer, including the concept of cancer immunosurveillance and immune escape. Current immunotherapeutic strategies and emerging results from ongoing clinical trials are presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Park, J.-H., Adoro, S., Guinter, T., Erman, B., Alag, A. S., Catalfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Comprehensive genomic characterization of head and neck squamous cell carcinomas
The Cancer Genome Atlas Network (2015) · Nature · doi:10.1038/nature14129 · Cited by 3,877
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Dewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,231
Prostaglandins as modulators of immunity
Harris, S. G., Padilla, J., Koumas, L., Ray, D., & Phipps, R. P. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(01)02154-8 · Cited by 1,180
Lymphocyte-Mediated Cytotoxicity
Russell, J. H., & Ley, T. J. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100201.131730 · Cited by 1,122
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,113
Natural Cell-Mediated Immunity
(1978) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60936-7 · Cited by 1,053
Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,022
Zeng, J., See, A. P., Phallen, J., Jackson, C. M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T. J., Albesiano, E., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.025 · Cited by 889
Lyford-Pike, S., Peng, S., Young, G. D., Taube, J. M., Westra, W. H., Akpeng, B., Bruno, T. C., Richmon, J. D., Wang, H., Bishop, J. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2384 · Cited by 777
A review of clinical trials of human papillomavirus prophylactic vaccines
Schiller, J. T., Castellsagué, X., & Garland, S. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.108 · Cited by 747 · cited 1×
“9% to 100%) in prevention of benign and malignant HPV-associated cervical lesions.(68) The effects of the vaccination on oropharyngeal lesion has not yet been fully evaluated but is expected to have promising results, considering the achieved antiviral results so far and the rising prevalence of HPVpositive oropharynx…”
BackgroundBadoual, C., Hans, S., Merillon, N., Van Ryswick, C., Ravel, P., Benhamouda, N., Levionnois, E., Nizard, M., Si-Mohamed, A., Besnier, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2606 · Cited by 633
Cancer risk after renal transplantation in the nordic countries, 1964–1986
Birkeland, S. A., Storm, H. H., Lamm, L. U., Barlow, L., Blohmé, I., Forsberg, B., Eklund, B., Fjeldborg, O., Friedberg, M., Frödin, L., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600209 · Cited by 613
Clinical significance of macrophage heterogeneity in human malignant tumors
Komohara, Y., Jinushi, M., & Takeya, M. (2014) · Cancer Science · doi:10.1111/cas.12314 · Cited by 551
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies
Yewale, C., Baradia, D., Vhora, I., Patil, S., & Misra, A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.100 · Cited by 533
Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment
Kortylewski, M., Xin, H., Kujawski, M., Lee, H., Liu, Y., Harris, T., Drake, C., Pardoll, D., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.018 · Cited by 474
Herrero, R., Quint, W., Hildesheim, A., Gonzalez, P., Struijk, L., Katki, H. A., Porras, C., Schiffman, M., Rodriguez, A. C., Solomon, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068329 · Cited by 473
Strauss, L., Bergmann, C., Szczepanski, M., Gooding, W., Johnson, J. T., & Whiteside, T. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0472 · Cited by 453
The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response
Stamell, E. F., Wolchok, J. D., Gnjatic, S., Lee, N. Y., & Brownell, I. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.03.017 · Cited by 387
Cosmi, L., Liotta, F., Lazzeri, E., Francalanci, M., Angeli, R., Mazzinghi, B., Santarlasci, V., Manetti, R., Vanini, V., Romagnani, P., et al. (2003) · Blood · doi:10.1182/blood-2003-04-1320 · Cited by 383
A Critical Role for Stat3 Signaling in Immune Tolerance
Cheng, F., Wang, H.-W., Cuenca, A., Huang, M., Ghansah, T., Brayer, J., Kerr, W. G., Takeda, K., Akira, S., Schoenberger, S. P., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00232-2 · Cited by 377
At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
Callahan, M. K., & Wolchok, J. D. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212631 · Cited by 348
Interleukin‐6 predicts recurrence and survival among head and neck cancer patients
Duffy, S. A., Taylor, J. M. G., Terrell, J. E., Islam, M., Li, Y., Fowler, K. E., Wolf, G. T., & Teknos, T. N. (2008) · Cancer · doi:10.1002/cncr.23615 · Cited by 330
Ferris, R. L., Jaffee, E. M., & Ferrone, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6360 · Cited by 320
Self-citationRadiation Therapy to Convert the Tumor Into an In Situ Vaccine
Formenti, S. C., & Demaria, S. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.06.020 · Cited by 319
Srivastava, R. M., Lee, S. C., Andrade Filho, P. A., Lord, C. A., Jie, H.-B., Davidson, H. C., López-Albaitero, A., Gibson, S. P., Gooding, W. E., Ferrone, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2426 · Cited by 318
Self-citationYang, Z.-Z., Grote, D. M., Ziesmer, S. C., Niki, T., Hirashima, M., Novak, A. J., Witzig, T. E., & Ansell, S. M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59806 · Cited by 309
Strauss, L., Bergmann, C., Gooding, W., Johnson, J. T., & Whiteside, T. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1403 · Cited by 281
Verbrugge, I., Hagekyriakou, J., Sharp, L. L., Galli, M., West, A., McLaughlin, N. M., Duret, H., Yagita, H., Johnstone, R. W., Smyth, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0210 · Cited by 275
Immunobiology of HPV and HPV vaccines
Stanley, M. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.02.003 · Cited by 271
Pak, A. S., Wright, M. A., Matthews, J. P., Collins, S. L., Petruzzelli, G. J., & Young, M. R. I. (1995) · PubMed · Cited by 271
Jie, H.-B., Schuler, P. J., Lee, S. C., Srivastava, R. M., Argiris, A., Ferrone, S., Whiteside, T. L., & Ferris, R. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2788 · Cited by 266
Self-citationKuss, I., Hathaway, B., Ferris, R. L., Gooding, W., & Whiteside, T. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0054 · Cited by 263
Self-citationLi, J., Jie, H.-B., Lei, Y., Gildener-Leapman, N., Trivedi, S., Green, T., Kane, L. P., & Ferris, R. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1215 · Cited by 246
Self-citationThe role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck
Zandberg, D. P., & Strome, S. E. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2014.04.003 · Cited by 239
Ferris, R. L., Whiteside, T. L., & Ferrone, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2750 · Cited by 221
Self-citationAugmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy
Taylor, C., Hershman, D., Shah, N., Suciu-Foca, N., Petrylak, D. P., Taub, R., Vahdat, L., Cheng, B., Pegram, M., Knutson, K. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0507 · Cited by 213
Näsman, A., Romanitan, M., Nordfors, C., Grün, N., Johansson, H., Hammarstedt, L., Marklund, L., Munck-Wikland, E., Dalianis, T., & Ramqvist, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038711 · Cited by 199
Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
Quezada, S. A., & Peggs, K. S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.117 · Cited by 190
Ogino, T., Shigyo, H., Ishii, H., Katayama, A., Miyokawa, N., Harabuchi, Y., & Ferrone, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0488 · Cited by 189
Human Papillomavirus Vaccines – Immune Responses
Stanley, M., Pinto, L. A., & Trimble, C. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.106 · Cited by 180
Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
Melero, I., Hirschhorn-Cymerman, D., Morales-Kastresana, A., Sanmamed, M. F., & Wolchok, J. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2065 · Cited by 176
Bourhis, J., Rivera, F., Mesia, R., Awada, A., Geoffrois, L., Borel, C., Humblet, Y., Lopez-Pousa, A., Hitt, R., Vega Villegas, M. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3547 · Cited by 174
Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion
Ferris, R. L., Lu, B., & Kane, L. P. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400557 · Cited by 173
Self-citationControl of NK cell functions by CD4+CD25+ regulatory T cells
Ralainirina, N., Poli, A., Michel, T., Poos, L., Andrès, E., Hentges, F., & Zimmer, J. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0606409 · Cited by 170
Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer
Bauernhofer, T., Kuss, I., Henderson, B., Baum, A. S., & Whiteside, T. L. (2003) · European Journal of Immunology · doi:10.1002/immu.200390014 · Cited by 164
Pallandre, J., Brillard, E., Créhange, G., Radlovic, A., Rémy-Martin, J.-P., Saas, P., Rohrlich, P., Pivot, X. B., Ling, X., Tiberghien, P., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7593 · Cited by 161
López-Albaitero, A., Lee, S. C., Morgan, S., Grandis, J. R., Gooding, W. E., Ferrone, S., & Ferris, R. L. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0697-4 · Cited by 160
Self-citationDasgupta, S., Bhattacharya-Chatterjee, M., O’Malley, B. W., & Chatterjee, S. K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5541 · Cited by 158
Lee, S. C., Srivastava, R. M., López-Albaitero, A., Ferrone, S., & Ferris, R. L. (2011) · Immunologic Research · doi:10.1007/s12026-011-8231-0 · Cited by 156
Self-citationLópez‐Albaitero, A., Nayak, J. V., Ogino, T., Machandia, A., Gooding, W. E., DeLeo, A. B., Ferrone, S., & Ferris, R. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3402 · Cited by 156
Self-citationPhase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer
Schuler, P. J., Harasymczuk, M., Visús, C., DeLeo, A. B., Trivedi, S., Lei, Y. L., Argiris, A. E., Gooding, W. E., Butterfield, L. H., Whiteside, T. L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2617 · Cited by 152
Self-citationJain, A. B., Reyes, J., Kashyap, R., Rohal, S., Abu-Elmagd, K. M., Starzl, T., & Fung, J. J. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00016 · Cited by 145
Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy
Brun, J.-L., Dalstein, V., Lévêque, J., Mathevet, P., Raulic, P., Baldauf, J., Scholl, S., Huynh, B., Douvier, S., Riethmuller, D., et al. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.09.020 · Cited by 145
Immune checkpoint blockade immunotherapy to activate anti‐tumour T ‐cell immunity
Ramsay, A. G. (2013) · British Journal of Haematology · doi:10.1111/bjh.12380 · Cited by 138
Seiwert, T. Y., Burtness, B. A., Weiss, J., Gluck, I., Eder, J. P., Pai, S. I., Dolled-Filhart, M. P., Emancipator, K., Pathiraja, K., Gause, C. K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.6011 · Cited by 133
Sun, Y., Chin, Y. E., Weisiger, E., Malter, C., Tawara, I., Toubai, T., Gatza, E., Mascagni, P., Dinarello, C. A., & Reddy, P. R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804388 · Cited by 132
Johnson, B. F., Clay, T. M., Hobeika, A. C., Lyerly, H. K., & Morse, M. A. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.4.449 · Cited by 124
Grizzle, W. E., Xu, X., Zhang, S., Stockard, C. R., Liu, C., Yu, S., Wang, J., Mountz, J. D., & Zhang, H. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2007.10.003 · Cited by 123
Promising systemic immunotherapies in head and neck squamous cell carcinoma
Gildener‐Leapman, N., Ferris, R. L., & Bauman, J. E. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.09.009 · Cited by 122
Self-citationSTAT3-mediated anti-inflammatory signalling
Murray, P. J. (2006) · Biochemical Society Transactions · doi:10.1042/bst0341028 · Cited by 113
Immunotherapy: target the stroma to hit the tumor
Kammertoens, T., Schüler, T., & Blankenstein, T. J. F. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.03.002 · Cited by 108
Leibowitz, M. S., Filho, P. A. A., Ferrone, S., & Ferris, R. L. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0961-7 · Cited by 106
Self-citationEvasion of host immunity directed by papillomavirus-encoded proteins
O’Brien, P. M., & Campo, M. S. (2002) · Virus Research · doi:10.1016/s0168-1702(02)00123-5 · Cited by 104
Sega, E. I., Leveson-Gower, D. B., Florek, M., Schneidawind, D., Luong, R. H., & Negrin, R. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086551 · Cited by 100
Grandis, J. R., Falkner, D. H., Melhem, M. F., Gooding, W. E., Drenning, S. D., & Morel, P. A. (2000) · PubMed · Cited by 99
Lathers, D. M. R. (2004) · Cytokine · doi:10.1016/j.cyto.2003.11.005 · Cited by 97
Targeting Angiogenesis in Head and Neck Cancer
Seiwert, T. Y., & Cohen, E. E. W. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.03.005 · Cited by 94
Mizukami, Y., Kono, K., Maruyama, T., Watanabe, M., Kawaguchi, Y., Kamimura, K., & Fujii, H. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604715 · Cited by 89
Leibowitz, M. S., Srivastava, R. M., Filho, P. A. A., Egloff, A. M., Wang, L., Seethala, R. R., Ferrone, S., & Ferris, R. L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1517 · Cited by 82
Self-citationInvestigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer
Jebreel, A., Mistry, D., Loke, D., Dunn, G., Hough, V. C., Oliver, K., Stafford, N., & Greenman, J. (2006) · The Journal of Laryngology & Otology · doi:10.1017/s0022215106002428 · Cited by 82
Segal, N. H., Ou, S. I., Balmanoukian, A. S., Fury, M. G., Massarelli, E., Brahmer, J. R., Weiss, J., Schöffski, P., Antonia, S. J., Massard, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3011 · Cited by 80
Epidemiology of Head and Neck Squamous Cell Cancer Among HIV-Infected Patients
DʼSouza, G., Carey, T. E., William, W. N., Nguyen, M. L., Ko, E. C., Riddell, J., Pai, S. I., Gupta, V., Walline, H. M., Lee, J. J., et al. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000083 · Cited by 75
Self-citationRegulation of immune responses to HPVinfection and during HPV‐directed immunotherapy
Bhat, P., Mattarollo, S. R., Gosmann, C., Frazer, I. H., & Leggatt, G. R. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00966.x · Cited by 73
Stephenson, R. M., Lim, C. M., Matthews, M., Dietsch, G. N., Hershberg, R. M., & Ferris, R. L. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1437-3 · Cited by 73
Self-citationImmune Cells in the Tumor Microenvironment
Whiteside, T. L. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-5357-1_27 · Cited by 68
Whiteside, T. L. (1998) · PubMed · Cited by 65
Strauss, L., Bergmann, C., & Whiteside, T. L. (2007) · International Journal of Cancer · doi:10.1002/ijc.23001 · Cited by 63
TGF-β and tumors — an ill-fated alliance
Moutsopoulos, N. M., Wen, J., & Wahl, S. M. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.04.003 · Cited by 58
Alhamarneh, O., Amarnath, S., Stafford, N. D., & Greenman, J. (2008) · Head & Neck · doi:10.1002/hed.20739 · Cited by 58
Madkan, V. K., Cook‐Norris, R. H., Steadman, M. C., Arora, A., Mendoza, N., & Tyring, S. K. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07961.x · Cited by 53
Prostaglandin E2 pathway in head and neck squamous cell carcinoma
Camacho, M., León, X., Fernández‐Figueras, M. T., Quer, M., & Vila, L. (2008) · Head & Neck · doi:10.1002/hed.20850 · Cited by 50
Seiwert, T. Y. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9268 · Cited by 40
Vermorken, J. B., Mesı́a, R., Vega-Villegas, M. E., Remenár, É., Hitt, R., Kawecki, A., Rottey, S., Zabolotnyy, D., Erfan, J., & Amellal, N. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.5537 · Cited by 21
Weise, J. B., Csiszár, K., Gottschlich, S., Hoffmann, M., Schmidt, A., Weingartz, U., Adamzik, I.-D., Heiser, A., Kabelitz, D., Ambrosch, P., et al. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.2.317 · Cited by 21
Cited by
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Self-citationThe molecular landscape of head and neck cancer
Leemans, C. R., Snijders, P. J. F., & Brakenhoff, R. H. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.11 · Cited by 1,395
Extracellular vesicles as tools and targets in therapy for diseases
Kumar, M. A., Baba, S. K., Sadida, H. Q., Marzooqi, S. A., Jerobin, J., Altemani, F. H., Algehainy, N., Alanazi, M. A., Abou-Samra, A.-B., Kumar, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01735-1 · Cited by 1,343
The changing therapeutic landscape of head and neck cancer
Cramer, J. D., Burtness, B., Le, Q. T., & Ferris, R. L. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0227-z · Cited by 783
Self-citationCohen, E. E. W., Bell, R. B., Bifulco, C. B., Burtness, B., Gillison, M. L., Harrington, K. J., Le, Q.-T., Lee, N. Y., Leidner, R., Lewis, R. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0662-5 · Cited by 722
Self-citation
Metadata
- Authors
- Ferris, R. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-10-10
- Volume
- 33
- Issue
- 29
- Pages
- 3293-3304
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2163814058
- Cited by
- 668
- References
- 99
- FWCI
- 21.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.